| Literature DB >> 35187889 |
Jie Luo1,2, Zhimin Song2, Tao Zhang1, Ketan Chu1, Jingyi Li1, Jianhong Zhou3,4,5, Jun Lin6,7,8.
Abstract
At present, endometriosis remains a worldwide health burden, with the main symptoms of dysmenorrhea, chronic pelvic pain, and infertility, markedly reducing the quality of life (de Ziegler et al., 2010). Although there is no proof that the disease is associated with high mortality, this disorder can significantly contribute to the deterioration of women's general well-being (McPeak et al., 2018). The main current treatment for endometriosis is surgery to remove endometriotic lesions; however, the recurrence rate following surgical treatment is as high as 21.5% at two years and 40.0%-50.0% at five years post-surgery (Koga et al., 2015). To prevent recurrence, adjuvant treatment with drugs after surgery is recommended to prolong relapse-free intervals. However, it is inconvenient for patients to continuously use such medications in terms of adverse effects and cost (Turk, 2002).Entities:
Mesh:
Substances:
Year: 2022 PMID: 35187889 PMCID: PMC8861560 DOI: 10.1631/jzus.B2100502
Source DB: PubMed Journal: J Zhejiang Univ Sci B ISSN: 1673-1581 Impact factor: 3.066